Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Imatinib (IMA) Low Dose Reduction Program (LDR) in Chronic Myeloid Leukemia Ph+ (CML Ph+) in a Single Reference Institution in Mexico City. Ongoing Preliminary Results

Rafael Hurtado Monroy, MD, Pablo Vargas-Viveros, MD, Carrillo Munoz Silvia, RN

Blood (2019) 134 (Supplement_1): 5921.

https://doi.org/10.1182/blood-2019-130873

Published: 2019

Journal Articles

Significant Improvement In Quality Of Life (QoL) In Patients With Chronic Myeloproliferative Neoplasms and Myelofibrosis Treated With JAK-1 and JAK-2 Inhibitor Ruxolitinib. A Single Institution Experience In Mexico

Pablo Vargas-Viveros, MD, Rafael Hurtado Monroy, MD, Myrna Candelaria-Hernandez, MD

Blood (2013) 122 (21): 5252.

https://doi.org/10.1182/blood.V122.21.5252.5252

Published: 2013

Journal Articles

Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph +) In IM-Resistant Disease. Report Of 14 New Cases From A Single Center In Mexico

Rafael Hurtado Monroy, MD, Pablo Vargas-Viveros, MD, Eduardo Cervera Ceballos, MD, Judith Cruz Velazquez, Silvia Carrillo Munos, RN

Blood (2013) 122 (21): 5172.

https://doi.org/10.1182/blood.V122.21.5172.5172

Published: 2013

Journal Articles

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Giovanni Barosi, MD, Mohan Agarwal, MD, MNAMS, Sonja Zweegman, MD, PhD, Wolfgang Willenbacher, MD, Sima Pakstyte, MD, Reinier Raymakers, MD, PhD, Nathan Cantoni, MD, Ankur Modi, Mahmudul Khan, PhD, Jose Ricardo Perez, MD, Hans Hasselbalch, MD, Jose Pablo Vargas Viveros, MD, Camila C.G. Linardi, MD, PhD, Heinz Gisslinger, MD, Adelmo Henrique Daumas Gabriel, MD, Francesca Palandri, David Lavie, MD, Claire N Harrison, DM FRCP FRCPath

Blood (2012) 120 (21): 2844.

https://doi.org/10.1182/blood.V120.21.2844.2844

Published: 2012

Journal Articles

Chronic Myeloid Leukemia Philadelphia Chromosome Positive (CML Ph+) with Imatinib (IM) Intolerance or Resistant Disease. Response to Thalidomide (TALI) Treatment. Preliminary Report of a Serial of Cases with Encouraging Results

Rafael Hurtado, MD, Jose Pablo Vargas Viveros, MD, Carrillo Muñoz Silvia, RN, Judith Cruz-Velazquez, Myrna Candelaria, MD, PhD, Eduardo Cervera, MD

Blood (2012) 120 (21): 1689.

https://doi.org/10.1182/blood.V120.21.1689.1689

Published: 2012

Journal Articles

Hyper Immunoglobulin E Syndrome (HIES): Report of a New Case Treated with Omalizumab and Dexametasone

Luis Fernando Cortázar-Benítez, R.M. Rojas Sotelo, Pablo Vargas-Viveros, MD, Rafael Hurtado-Monroy, MD., Catalina Romo Aguirre, MD, Jorge Valenzuela Tamariz, MD, Alejandra Zárate, MD, Sergio Masse, MD

Blood (2011) 118 (21): 4934.

https://doi.org/10.1182/blood.V118.21.4934.4934

Published: 2011

Journal Articles

Hemolytic Intravascular Anemia (HIA) Microangiopathic-Like and Deep Venous Thrombosis (DVT) Due to Ozone Exposure: Case Report

Luis Fernando Cortázar-Benítez, Pablo Vargas Viveros, MD, Alfredo Aiza Alvarez, Rafael Hurtado Monroy, MD.

Blood (2011) 118 (21): 5278.

https://doi.org/10.1182/blood.V118.21.5278.5278

Published: 2011

Journal Articles

Imatinib Alone (IA) Vs. Imatinib + Ara-C (IMAC): A Randomized Phase III Clinical Trial for the Treatment of Early Phase (EP) Chronic Myeloid Leukemia (CML) Ph+. Preliminary Report of Mexican Cooperative Leukemia Group (GRUMELA).

Rafael Hurtado Monroy, MD, Pablo Vargas-Viveros, MD, Eduardo Cervera, MD, Myrna Candelaria, MD, Alvaro Aguayo, MD, Emma Gallardo, MD, Eucario Leon, MD, Juan Labardini, MD, Ricardo Sosa, MD, Rogelio Paredes, MD, Fernando Romero, MD, Oscar Perez, MD, Omar Coronel-Ayala, MD

Blood (2004) 104 (11): 1015.

https://doi.org/10.1182/blood.V104.11.1015.1015

Published: 2004

NARROW

Imatinib (IMA) Low Dose Reduction Program (LDR) in Chronic Myeloid Leukemia Ph+ (CML Ph+) in a Single Reference Institution in Mexico City. Ongoing Preliminary Results

Significant Improvement In Quality Of Life (QoL) In Patients With Chronic Myeloproliferative Neoplasms and Myelofibrosis Treated With JAK-1 and JAK-2 Inhibitor Ruxolitinib. A Single Institution Experience In Mexico

Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph +) In IM-Resistant Disease. Report Of 14 New Cases From A Single Center In Mexico

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Chronic Myeloid Leukemia Philadelphia Chromosome Positive (CML Ph+) with Imatinib (IM) Intolerance or Resistant Disease. Response to Thalidomide (TALI) Treatment. Preliminary Report of a Serial of Cases with Encouraging Results

Hyper Immunoglobulin E Syndrome (HIES): Report of a New Case Treated with Omalizumab and Dexametasone

Hemolytic Intravascular Anemia (HIA) Microangiopathic-Like and Deep Venous Thrombosis (DVT) Due to Ozone Exposure: Case Report

Imatinib Alone (IA) Vs. Imatinib + Ara-C (IMAC): A Randomized Phase III Clinical Trial for the Treatment of Early Phase (EP) Chronic Myeloid Leukemia (CML) Ph+. Preliminary Report of Mexican Cooperative Leukemia Group (GRUMELA).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only